<DOC>
	<DOC>NCT00732992</DOC>
	<brief_summary>This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.</brief_summary>
	<brief_title>A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients with a diagnosis of a solid malignancy that is refractory to standard therapy or for which no standard therapy exists. Patients has a good performance status (ECOG 0 or 1) Prior treatment with either pemetrexed or SU011248. Coughing up blood within 4 weeks before starting study treatment (small amounts okey). Hypertension that cannot be controlled by medications.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>malignancy</keyword>
	<keyword>sunitinib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>phase 1</keyword>
	<keyword>neoplasms</keyword>
</DOC>